Amnestix Overview
- Year Founded
-
2006
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$6.3M
Amnestix General Information
Description
Operator of a biopharmaceutical company intended to develop drugs for memory-related disorders. The company focuses on developing small-molecule compounds that could be used in the treatment of Alzheimer's disease, dementia, and similar neurological conditions.
Contact Information
Website
www.amnestix.comCorporate Office
- 800 Airport Road
- Suite 508
- Burlingame, CA 94010
- United States
Corporate Office
- 800 Airport Road
- Suite 508
- Burlingame, CA 94010
- United States
Amnestix Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
3. Merger/Acquisition | 08-Jun-2008 | $6.3M | Completed | Generating Revenue | ||
2. Early Stage VC (Series A) | 09-Mar-2007 | Completed | Startup | |||
1. University Spin-Out | 01-Jan-2006 | Completed | Startup |
Amnestix Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series A |
Amnestix Patents
Amnestix Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20100160297-A1 | Compounds for pim kinase inhibition and for treating malignancy | Inactive | 12-May-2008 | ||
EP-2296472-A1 | Compounds for rho kinase inhibition and for improving learning and memory | Inactive | 12-May-2008 | ||
US-20110237600-A1 | Compounds for improving learning and memory | Inactive | 12-May-2008 | ||
CA-2723472-A1 | Compounds for rho kinase inhibition and for improving learning and memory | Inactive | 12-May-2008 | ||
AU-2009257926-A1 | Compounds for rho kinase inhibition and for improving learning and memory | Inactive | 12-May-2008 | A61K31/47 |
Amnestix Former Investors (1)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Brain Trust Accelerator Fund | Venture Capital | Minority |
Amnestix FAQs
-
When was Amnestix founded?
Amnestix was founded in 2006.
-
Where is Amnestix headquartered?
Amnestix is headquartered in Burlingame, CA.
-
What industry is Amnestix in?
Amnestix’s primary industry is Biotechnology.
-
Is Amnestix a private or public company?
Amnestix is a Private company.
-
What is the current valuation of Amnestix?
The current valuation of Amnestix is
. -
What is Amnestix’s current revenue?
The current revenue for Amnestix is
. -
How much funding has Amnestix raised over time?
Amnestix has raised $520K.
-
Who are Amnestix’s investors?
Brain Trust Accelerator Fund has invested in Amnestix.
-
When was Amnestix acquired?
Amnestix was acquired on 08-Jun-2008.
-
Who acquired Amnestix?
Amnestix was acquired by X-Pol Biotech.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »